Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totaling 4,577 shares, an increase of 1,702.0% from the April 15th total of 254 shares. Based on an average daily trading volume, of 3 shares, the days-to-cover ratio is currently 1,525.7 days. Approximately 0.0% of the company’s stock are sold short.
Basilea Pharmaceutica Price Performance
Shares of BPMUF stock remained flat at $69.00 on Monday. The company has a current ratio of 5.11, a quick ratio of 4.68 and a debt-to-equity ratio of 0.59. The firm’s 50 day simple moving average is $70.39 and its 200-day simple moving average is $66.95. Basilea Pharmaceutica has a 1-year low of $57.70 and a 1-year high of $74.00.
About Basilea Pharmaceutica
Basilea Pharmaceutica AG is a Swiss biopharmaceutical company headquartered in Basel, specializing in the development and commercialization of innovative treatments for hospital‐treated diseases. The company’s research is focused primarily on anti‐infectives and oncology, with a portfolio that spans both marketed products and early‐ to late‐stage pipeline candidates. Basilea leverages medicinal chemistry expertise to address critical medical needs in fungal infections, bacterial infections and cancer.
Among its lead products is isavuconazole, a broad‐spectrum antifungal agent marketed under the trade name Cresemba.
Read More
- Five stocks we like better than Basilea Pharmaceutica
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
